Clinical Research Details An Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) in Subjects with X-linked Retinitis Pigmentosa caused by RPGR-ORF15 mutations (20172166) Study Description Phase IIa/b trial for gene therapy in X-linked Retinitis Pigmentosa Inclusion/Exclusion Criteria not enrolling Investigators Sandeep Grover, M.D. Ophthalmology